Recce Pharmaceuticals Ltd. (LS:A2ADQM) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Secured debt facility with warrants Terms changed: Warrants at A$0.29 Buyers: Avenue Capital Group (lender under the existing secured debt facility) Use of proceeds: Financial flexibility to support ongoing Phase 3 clinical trial programs | Oct 16, 2026 | |
| Share purchase plan of new fully paid ordinary shares (SPP Shares) with free-attaching unlisted options Update: up to A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1 Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead) Insiders: Participating directors can receive SPP Shares; their SPP Options are subject to shareholder approval at the EGM Use of proceeds: Same purposes as the Placement | Sep 2, 2026 | US$2.76M |
| Private placement of new fully paid ordinary shares with free-attaching unlisted options Announced: A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1 Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead) Use of proceeds: Strengthen balance sheet for Middle Eastern licensing deal, clinical trials, IND-enabling activities and working capital | Jun 26, 2026 | US$2.76M |
| Private placement of new fully paid ordinary shares Announced: A$5M · A$0.28 a share Use of proceeds: Commencement and completion of one of the Phase III clinical trials | Apr 10, 2025 | US$3.1M |
| Rights offering of new fully paid ordinary shares Announced: up to A$10.8M · A$0.28 a share Insiders: Each of the Directors who are Eligible Shareholders intends to participate in the Entitlement Offer Use of proceeds: Other programs currently in development by the Company | Apr 10, 2025 | US$6.7M |